Clinical Study of Thoracic Excluder Endoprosthesis to Treat Descending Thoracic Aortic Diseases
NCT ID: NCT00546312
Last Updated: 2010-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
332 participants
INTERVENTIONAL
2000-02-29
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of Thoracic Aortic Aneurysm Exclusion
NCT00549315
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
NCT01524211
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
NCT00435942
Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection
NCT03033043
Endovascular Repair of Descending Thoracic Aortic Aneurysms
NCT00802984
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The accepted treatment for aneurysms deemed to warrant intervention is surgical resection and repair. Operative and post operative complications contributing to early mortality after surgical repair of descending thoracic aortic aneurysms include low cardiac output, pulmonary insufficiency, myocardial infarction, postoperative hemorrhage, pulmonary embolism and sepsis.
In addition to mortality, two of the gravest complications of this surgical procedure, neurologic complications due to spinal cord ischemia, such as paraplegia and paraparesis, and renal failure or dysfunction, remain common.
Dissections, another disease process of the descending thoracic aorta, are rare. Aortic dissections are thought to start with a tear or disruption of the intimal lining of the aorta, either due to medial degenerative diseases, trauma or rupture of an ulcerated intimal plaque. Blood at systemic arterial pressures invades the underlying medial layer of the aortic wall, dissecting the layers of the aortic wall, and forming a false lumen. The dissection then propagates for varying distances and in varying directions along the length of the aorta.
As the false lumen increases in size, arterial flow to the true aortic lumen and to arteries arising from the aorta may be blocked or disrupted. Depending upon the location of the primary intimal tear and the direction of dissection propagation, various vital organs may loose arterial blood supply, and the aorta may rupture into the pericardial sac or pleural space, leading to cardiac tamponade or free pleural rupture. Blood flow from the false lumen may reenter the true lumen through another intimal tear, which may occur proximal or distal to the first, depending on the direction of dissection propagation.
Medical therapy is the first line treatment for dissections of the descending thoracic aorta, and is aimed at reducing the mean, peak and diastolic recoil arterial pressure and the dP/dt while maintaining sufficient pressure to adequately perfuse all vital organs. Surgical intervention is warranted for patients with progression of dissection, impending rupture, refractory hypertension, a sizable localized false aneurysmal component, or continued pain.
A device has been designed to treat disease processes of the descending thoracic aorta. The Thoracic EXCLUDER Endoprosthesis is a device that allows for primary endovascular repair of the descending thoracic aorta and is intended to be used as an intraluminal blood conduit. The Thoracic EXCLUDER Endoprosthesis is a flexible, self-expanding endoprosthesis that is constrained on the leading end of a delivery catheter. A separate balloon catheter, the Thoracic EXCLUDER Balloon Catheter, is used to smooth the endoprosthesis following implantation.
Subjects will undergo an evaluation of the endoprosthesis, and will also be evaluated for device and procedure related adverse events that may have occurred during the follow-up period. Follow-up will be completed at 1, 3, 6, 12, 24, 36, 48, and 60 months. Subject evaluation at 1 and 3 months will include a complete Physical Examination and a CT with contrast enhancement. Subject evaluation at 6, 12, 24, 36, 48, and 60 months will also undergo a complete Physical Examination, a CT with contrast enhancement, and a Chest X-Ray (AP, Lateral, and 2 obliques).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thoracic EXCLUDER Endoprosthesis
Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Anatomy meets Thoracic EXCLUDER Endoprosthesis specification criteria.
* Minimum 2 cm non-aneurysmal segment proximal and distal to the aneurysm.
* \< 60 angle in the aortic arch may require additional length of non- aneurysmal segment if the arch is included in the treatment segment.
* The patient is of a "high risk" status for surgical repair. The patient is characterized by the presence of co-morbid factors and/or thoracic aortic pathology that place the patient in a category of prohibitive risk for open repair, and, without intervention, and adverse event could be anticipated within days or weeks. The patient has an ASA score of IV or V.
* Ability to comply with protocol requirements including follow-up.
* Signed Informed Consent Form.
Exclusion Criteria
* Significant thrombus at the proximal or distal implantation sites.
* Planned occlusion of the left carotid or celiac arteries, unless supplemental conduit provided.
* Myocardial infarction within six weeks.
* Degenerative connective tissue disease, e.g. Marfan's or Ehler Danlos Syndrome, unless the proximal and distal implantation sites of the Thoracic EXCLUDER Endoprosthesis are located within previously placed surgical grafts.
* Female of child bearing potential with positive pregnancy test.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arizona Heart Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arizona Heart Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward B Diethrich, M.D.
Role: PRINCIPAL_INVESTIGATOR
Arizona Heart Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Heart Institute
Phoenix, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fann JI, Miller DC. Endovascular treatment of descending thoracic aortic aneurysms and dissections. Surg Clin North Am. 1999 Jun;79(3):551-74. doi: 10.1016/s0039-6109(05)70024-4.
Bickerstaff LK, Pairolero PC, Hollier LH, Melton LJ, Van Peenen HJ, Cherry KJ, Joyce JW, Lie JT. Thoracic aortic aneurysms: a population-based study. Surgery. 1982 Dec;92(6):1103-8.
Clouse WD, Hallett JW Jr, Schaff HV, Gayari MM, Ilstrup DM, Melton LJ 3rd. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA. 1998 Dec 9;280(22):1926-9. doi: 10.1001/jama.280.22.1926.
McNamara JJ, Pressler VM. Natural history of arteriosclerotic thoracic aortic aneurysms. Ann Thorac Surg. 1978 Nov;26(5):468-73. doi: 10.1016/s0003-4975(10)62927-x.
Najafi H. 1980: descending aortic aneurysmectomy without adjuncts to avoid ischemia. 1993 update. Ann Thorac Surg. 1993 Apr;55(4):1042-5. doi: 10.1016/0003-4975(93)90150-g.
von Segesser LK, Killer I, Jenni R, Lutz U, Turina MI. Improved distal circulatory support for repair of descending thoracic aortic aneurysms. Ann Thorac Surg. 1993 Dec;56(6):1373-80. doi: 10.1016/0003-4975(93)90684-a.
Hamerlijnck RP, Rutsaert RR, De Geest R, Brutel de la Riviere A, Defauw JJ, Vermeulen FE. Surgical correction of descending thoracic aortic aneurysms under simple aortic cross-clamping. J Vasc Surg. 1989 Apr;9(4):568-73.
Culliford AT, Ayvaliotis B, Shemin R, Colvin SB, Isom OW, Spencer FC. Aneurysms of the descending aorta. Surgical experience in 48 patients. J Thorac Cardiovasc Surg. 1983 Jan;85(1):98-104.
Carlson DE, Karp RB, Kouchoukos NT. Surgical treatment of aneurysms of the descending thoracic aorta: an analysis of 85 patients. Ann Thorac Surg. 1983 Jan;35(1):58-69. doi: 10.1016/s0003-4975(10)61432-4.
Cooley DA, Baldwin RT. Technique of open distal anastomosis for repair of descending thoracic aortic aneurysms. Ann Thorac Surg. 1992 Nov;54(5):932-6. doi: 10.1016/0003-4975(92)90652-k.
Dake MD, Miller DC, Mitchell RS, Semba CP, Moore KA, Sakai T. The
Borst HG, Jurmann M, Buhner B, Laas J. Risk of replacement of descending aorta with a standardized left heart bypass technique. J Thorac Cardiovasc Surg. 1994 Jan;107(1):126-32; discussion 132-3.
Lawrie GM, Earle N, De Bakey ME. Evolution of surgical techniques for aneurysms of the descending thoracic aorta: twenty-nine years experience with 659 patients. J Card Surg. 1994 Nov;9(6):648-61. doi: 10.1111/j.1540-8191.1994.tb00899.x.
Laschinger JC, Izumoto H, Kouchoukos NT. Evolving concepts in prevention of spinal cord injury during operations on the descending thoracic and thoracoabdominal aorta. Ann Thorac Surg. 1987 Dec;44(6):667-74. doi: 10.1016/s0003-4975(10)62163-7.
Rutherford RB; editor; Vascular Surgery, Fourth Edition; 1995, W. B. Saunders Co.
Bergan JJ, Yao JST; editors; Aneurysms, Diagnosis and Treatment; 1982, Grune and Straton
Fann JI, Miller DC. Aortic dissection. Ann Vasc Surg. 1995 May;9(3):311-23. doi: 10.1007/BF02135293. No abstract available.
Torchiana DF, Shin RD, Akins CW, Hilgenberg AD, et. al. Delayed management of traumatic thoracic aortic disruption. Poster abstract presented at the 35th annual meeting of the Society of Thoracic Surgeons, San Antonio, Texas, January 1999
Fann JI, Mitchell RS, Dake DC, Miller DC. Results of endovascular stent-grafting in patients with thoracic aortic aneurysm. Progress in Vascular Surgery chapter 19
Kato M, Matsuda T, Kaneko M, Kuratani T, Mizushima T, Seo Y, Uchida H, Kichikawa K, Maeda M, Ohnishi K. Outcomes of stent-graft treatment of false lumen in aortic dissection. Circulation. 1998 Nov 10;98(19 Suppl):II305-11; discussion II311-2.
Sacks D, Marinelli DL, Martin LG, Spies JB. Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. Technology Assessment Committee. J Vasc Interv Radiol. 1997 Jan-Feb;8(1 Pt 1):137-49. doi: 10.1016/s1051-0443(97)70530-x. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
G990299
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.